Qualigen Therapeutics Files Definitive Proxy Statement
Ticker: AIXC · Form: DEF 14A · Filed: Sep 10, 2024 · CIK: 1460702
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, governance
TL;DR
Qualigen Proxy Statement is IN. Get ready to vote on company matters.
AI Summary
Qualigen Therapeutics, Inc. filed its definitive proxy statement on September 9, 2024, for its annual meeting. The filing details the company's operations and governance, including information relevant to shareholder voting on corporate matters. The company is headquartered in Carlsbad, California, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides shareholders with crucial information to make informed decisions regarding company leadership and strategic direction at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new material financial or operational information that would inherently increase risk.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- 2042 CORTE DEL NOGAL (location) — Business Address
- CARLSBAD (location) — Business City
- CALIFORNIA (location) — Business State
- 92011 (location) — Business Zip Code
- RITTER PHARMACEUTICALS INC (company) — Former Company Name
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a definitive proxy statement, is filed by a company to provide shareholders with information they need to vote on matters at an upcoming shareholder meeting.
When was this definitive proxy statement filed?
This definitive proxy statement was filed on September 9, 2024.
What is the primary business of Qualigen Therapeutics, Inc.?
Qualigen Therapeutics, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
Where is Qualigen Therapeutics, Inc. located?
Qualigen Therapeutics, Inc. is located at 2042 CORTE DEL NOGAL, CARLSBAD, CALIFORNIA, 92011.
Did Qualigen Therapeutics, Inc. have a previous name?
Yes, Qualigen Therapeutics, Inc. was formerly known as RITTER PHARMACEUTICALS INC, with a name change date of April 2, 2009.
Filing Stats: 4,753 words · 19 min read · ~16 pages · Grade level 14.3 · Accepted 2024-09-09 19:18:05
Key Financial Figures
- $0.001 — e all shares of common stock, par value $0.001 per share, of the Company that you owne
Filing Documents
- formdef14a.htm (DEF 14A) — 614KB
- formdef14a_001.jpg (GRAPHIC) — 8KB
- 0001493152-24-035543.txt ( ) — 627KB
Security Ownership of Certain Beneficial Owners and Management
Security Ownership of Certain Beneficial Owners and Management 21 Report of the Audit Committee 22 Relationship with Independent Registered Public Accounting Firm 23 Fees and Services of Baker Tilly US, LLP 24 Proposal 1—Election of Directors 25 Proposal 2—Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm 26 Proposal 3—Approval of Reverse Stock Split 27 Proposal 4—Adjournment Proposal 34 Proposal 5—Stock Issuance Proposal 35 Proposal 6—“Say-on-Pay” Vote 37 Other Matters 38 Householding of Proxy Materials 39 The Company’s Website 40 The Company’s Principal Executive Office 41 Additional Questions and Information Regarding the Annual Meeting and Stockholder Proposals 42 What happens if additional proposals are presented at the Annual Meeting? 42 Who will bear the cost of soliciting votes for the Annual Meeting? 42 May I propose nominees for election to the board of directors at next year’s annual meeting of stockholders? 42 May I propose other business proposals for consideration at next year’s annual meeting of stockholders? 42 PROXY QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND THE 2024 ANNUAL MEETING OF STOCKHOLDERS Q: When and where is the 2024 Annual Meeting of Stockholders? A: The 2024 Annual Meeting of Stockholders (the “Annual Meeting”) will be held on October 25, 2024 at 10:00 a.m. Pacific Daylight Time at 5857 Owens Avenue, Suite 300, Carlsbad, California 92008. Q: Why is the Company providing these proxy materials? A: The board of directors of Qualigen Therapeutics, Inc. (“Qualigen,” the “Company,” “we,” “our,” or “us,” as the context requires) is soliciting proxies to be voted at the Annual Meeting. When we ask for your proxy, we must provide you with a proxy